We’ve recently updated our valuation analysis.

Novo Nordisk Valuation

Is NOVO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NOVO B?

Other financial metrics that can be useful for relative valuation.

NOVO B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue12.2x
Enterprise Value/EBITDA26.8x
PEG Ratio3.4x

Price to Earnings Ratio vs Peers

How does NOVO B's PE Ratio compare to its peers?

The above table shows the PE ratio for NOVO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average39.3x
ALK B ALK-Abelló
71.7x31.2%kr.24.6b
HLUN A H. Lundbeck
16.1x16.6%kr.26.0b
LLY Eli Lilly
51.7x20.8%US$320.8b
MRK Merck
18.5x11.0%US$263.8b
NOVO B Novo Nordisk
39.3x11.7%kr.2.2t


Price to Earnings Ratio vs Industry

How does NOVO B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a12.6%
n/an/an/a


Price to Earnings Ratio vs Fair Ratio

What is NOVO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NOVO B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.3x
Fair PE Ratio40.7x

Price-To-Earnings vs Fair Ratio: NOVO B is good value based on its Price-To-Earnings Ratio (39.3x) compared to the estimated Fair Price-To-Earnings Ratio (40.7x).


Share Price vs Fair Value

What is the Fair Price of NOVO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NOVO B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentkr.966.10
kr.960.52
-0.6%
16.8%kr.1,200.00kr.625.00n/a23
Jan ’24kr.938.00
kr.899.13
-4.1%
15.4%kr.1,085.00kr.540.00n/a23
Dec ’23kr.892.60
kr.872.50
-2.3%
15.9%kr.1,085.00kr.540.00n/a24
Nov ’23kr.801.00
kr.851.32
+6.3%
15.6%kr.1,070.00kr.540.00n/a25
Oct ’23kr.761.40
kr.836.08
+9.8%
16.5%kr.1,025.00kr.540.00n/a26
Sep ’23kr.773.30
kr.828.38
+7.1%
16.3%kr.1,025.00kr.540.00n/a26
Aug ’23kr.847.10
kr.827.46
-2.3%
16.9%kr.1,025.00kr.540.00n/a26
Jul ’23kr.784.60
kr.813.00
+3.6%
16.3%kr.1,005.00kr.540.00n/a26
Jun ’23kr.769.40
kr.795.88
+3.4%
17.5%kr.1,005.00kr.540.00n/a26
May ’23kr.812.30
kr.765.92
-5.7%
17.3%kr.960.00kr.540.00n/a24
Apr ’23kr.759.50
kr.709.67
-6.6%
15.2%kr.900.00kr.490.00n/a24
Mar ’23kr.696.40
kr.693.92
-0.4%
13.2%kr.838.00kr.490.00n/a24
Feb ’23kr.671.20
kr.664.96
-0.9%
16.0%kr.838.00kr.390.00kr.942.4025
Jan ’23kr.735.00
kr.675.46
-8.1%
16.5%kr.850.00kr.390.00kr.938.0024
Dec ’22kr.712.10
kr.678.96
-4.7%
18.0%kr.850.00kr.390.00kr.892.6024
Nov ’22kr.702.70
kr.627.29
-10.7%
17.1%kr.780.00kr.390.00kr.801.0024
Oct ’22kr.613.00
kr.608.04
-0.8%
17.7%kr.780.00kr.390.00kr.761.4025
Sep ’22kr.631.60
kr.594.77
-5.8%
19.0%kr.780.00kr.390.00kr.773.3026
Aug ’22kr.580.00
kr.492.00
-15.2%
15.3%kr.640.00kr.343.00kr.847.1027
Jul ’22kr.528.90
kr.474.19
-10.3%
12.3%kr.560.00kr.340.00kr.784.6027
Jun ’22kr.481.55
kr.469.22
-2.6%
11.8%kr.560.00kr.340.00kr.769.4027
May ’22kr.453.05
kr.467.54
+3.2%
11.9%kr.560.00kr.340.00kr.812.3027
Apr ’22kr.429.75
kr.466.85
+8.6%
12.2%kr.550.00kr.330.00kr.759.5026
Mar ’22kr.448.55
kr.466.85
+4.1%
12.2%kr.550.00kr.330.00kr.696.4026
Feb ’22kr.433.70
kr.456.33
+5.2%
12.5%kr.550.00kr.305.00kr.671.2027


Discover undervalued companies